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the procedural success rate will be much higher than at 
present and the need for emergency surgery minimized. 
In these initial cases, we l used device sizes twice the 
balloon-sized diameter. 2 With experience, we have deter- 
mined that we can successfully use ratios between 1.2 and 
1.5, and, so long as the conjoint suture ring diameter 2 is as 
large as the anatomic diameter of the ASD, residual 
shunts are uncommon. The transient complete heart block 
(which did not require temporary pacing) was probably 
related to the large-sized evice used. 
Percutaneous closure of ASDs in human beings, who 
have thin compliant atrial septa and great variability of the 
size and position of the defects, is more difficult than the 
closure of experimentally created circular defects in the 
thick muscular atrial septa of dogs. 2 This device is self- 
centering and hence the anatomic riteria for selection of 
suitable candidates for this device is being actively inves- 
tigated. 
Surgical closure is the "gold standard" for the closure of 
ASDs. All three patients who needed emergency surgery 
in the series reported by Agarwal, Ghosh, and Mittal 1 
were adults. In a surgical series of 166 adult patients with 
ASDs, Horvath and associates 3 reported an early mortal- 
ity rate of only 1.2% but a perioperative complication rate 
of 13%. The complications included arrhythmias necessi- 
tating cardioversion, reoperation for bleeding, air embo- 
lism, tamponade, congestive heart failure, cerebrovascular 
accident, transient ischemic attack, complete heart block, 
and respiratory failure. Obviously these two reports can- 
not be directly compared. In the next phase of the U.S. 
arm of the trials we will be formally comparing device 
closure and surgical closure in patients with identical entry 
criteria. 
We hope that with greater experience in the use of this 
device, careful ong-term follow-up, and comparison with 
surgical closure in a structured clinical trial, we will be 
able to determine the role of this new investigational 
device for the percutaneous closure of ASDs. 
Gladwin S. Das, MD 
Cardiovascular Division 
University of Minnesota Hospital and Clinic 
Minneapolis, MN 55455 
REFERENCES 
!. Agarwal SK, Ghosh PK, Mittal PK. Failure of devices used for 
closure of atrial septal defects: mechanisms and management. 
J Thorac Cardiovascular Surg 1996;112:21-6. 
2. Das GS, Voss G, Jarvis G, Wyche K, Gunther R, Wilson RF. 
Experimental trial septaI defect closure with a new transcath- 
eter, self-centering device. Circulation 1993;88(Suppl):1754- 
64. 
3. Horvath KA, Burke RP, Collins J J, Cohn LH. Surgical treat- 
ment of adult atrial septal defect: early and Long term results. 
J Am Coil Cardiol 1992;20:1156-9. 
12/8/77709 
Reply to the Editor." 
The response of Dr. Das has aptly focused on the 
current deficiencies of atrial septal defect (ASD) closure 
devices and the limitations of extrapolating data from 
animal trials to therapeutic use in human beings. It was in 
this perspective that we proposed the currently relevant 
indications for the use of ASD closure devices. We shall 
not play Nostradamus. When Dr. Das's newer trial with a 
lower device/defect ratio and new retrieval system be- 
comes reproducibly effective, it may change the therapeu- 
tic approach to closure of ASDs. 
Probal K. Ghosh, MCh, FRCSE 
Surendra K. Agarwal, MCh 
Pramod K. Mittal, MCh 
Department of Cardiovascular and Thoracic Surgery 
Sanjay Gandhi PG Institute of Medical Science 
Lucknow 226 014, India 
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Purulent pericarditis 
To the Editor: 
We are very interested in the article by Mann-Segal and 
associates, 1 concerning successful treatment of purulent 
pericarditis by irrigation of fibrinolytics, and we fully 
support his technique. We 2 previously reported the use of 
intrapericardial urokinase to dissolve pericardial fibrin 
layers in three patients, and the drug was well tolerated in 
these patients. Mann-Segal did not mention laboratory 
tests in his report; in our patients no changes occurred 
either in hemodynamic or in coagulation parameters 
during the period of intrapericardial fibrinolytic therapy. 
Our safety measures included echocardiography during 
instillation to detect iatrogenic right heart compression 
and warming of the irrigation fluid to prevent arrhythmias. 
We used urokinase for the lysis of pericardial fibrin 
deposits because urokinase has equal fibrinolytic potency 
but less antigenic potency than streptokinase. 3 The effi- 
cacy of urokinase in dissolving extravascular fibrin has 
been demonstrated especially in the pleural cavity by 
intrapleural administrationJ '5 
Fibrinolytic pericardial irrigation with urokinase as well 
as streptokinase seems to be a promising treatment of 
exudative fibrinous pericarditis, which can prevent con- 
strictive pericarditis without surgical intervention. The 
ideal dose and treatment regimen, however, remain to be 
defined. 
W.-B. Winkler, MD 
R. Karnik, MD 
Z Slany, MD 
Department of Internal Medicine II 
Krankenanstalt Rudolfstiftung 
A-1030 Wien, Austria 
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